-
Yantai Dongcheng Pharma Secures FDA Fast-Track Designation for 177Lu-LNC1004 in Thyroid Cancer
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received fast-track designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy, 177Lu-LNC1004, in patients with metastatic iodine-131 refractory differentiated thyroid cancer who have previously undergone treatment with at least one tyrosine kinase…
-
Dongcheng Pharma Moves to Enhance Portfolio with Acquisition of Rongcheng Medical’s GSA Injection
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its intention to acquire full rights to the 99mTc GSA Injection and GSA cold kit from domestic rival Rongcheng Medical Technology Wuxi Co., Ltd., for a purchase price of RMB 85 million (approximately USD 11.82 million). The 99mTc GSA…
-
Yantai Dongcheng Pharmaceutical’s 18F-LNC1007 Receives Clinical Clearance for Solid Tumor Diagnostics
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received clinical trial approval from the National Medical Products Administration (NMPA) for its 18F-LNC1007 injection, a novel radioactive diagnostic drug. This drug is designed to target fibroblast activating protein (FAP) and integrin alpha-v beta-3, which are biomarkers…
-
Yantai Dongcheng Pharmaceutical Secures NMPA Nod for PSMA-Targeted Radiotherapeutic Drug
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a leading pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug, 177LuLNC1011. This novel therapeutic is a prostate specific membrane antigen (PSMA)-targeted radioactive in vivo treatment…
-
Yantai Dongcheng Pharmaceutical Gets NMPA Approval for ⁹⁹ᵐTc Tetrofosmin Imaging Agent
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its ⁹⁹ᵐTc tetrofosmin, a SPECT myocardial perfusion imaging agent. This radiopharmaceutical drug, which is utilized for myocardial perfusion imaging in…
-
Yantai Dongcheng Pharmaceutical’s 177LuLNC1011 Gets FDA Green Light for Prostate Cancer Clinical Trial
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its prostate specific membrane antigen (PSMA)-targeted radioactive in vivo therapeutic drug, 177LuLNC1011. The molecule is intended for evaluation…
-
Yantai Dongcheng Pharmaceutical Receives NMPA Approval for SSTR2 Targeted Radioactive Drug
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its drug candidate, 177LuLNC1010. This investigational therapy is a somatostatin receptor 2 (SSTR2) targeted radioactive drug designed for the…
-
Yantai Dongcheng Pharmaceutical’s Radiopharmaceutical 18F-LNC1007 Cleared for Australian Phase I Trial
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that its radioactive diagnostic drug, 18F-LNC1007 injection, has successfully passed a safety review conducted by the US Food and Drug Administration (FDA). This clearance paves the way for the drug to commence a Phase I clinical…
-
Yantai Dongcheng Pharmaceutical Receives NMPA Approval for Advanced Solid Tumor Therapy
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a leading pharmaceutical company based in China, has announced that it has been granted clinical trial approval by the National Medical Products Administration (NMPA) for its innovative drug, 177Lu-LNC1008. This targeted radioactive in vivo therapeutic drug is designed to treat general advanced…
-
Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has successfully raised RMB 300 million (USD 41.4 million) in a Series B+ financing round. The funding round was led by Shenzhen Capital Group, with participation from Qianhai Ark Asset Management…
-
Yantai Dongcheng Secures Approval for Phase I Study of 68Ga-LNC1007 in Singapor
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has received approval from the Health Sciences Authority of Singapore to initiate a Phase I clinical study for its radiopharmaceutical candidate, 68Ga-LNC1007. This diagnostic agent targets fibroblast activating protein (FAP) and integrin αvβ3, and is being developed to aid in the treatment…
-
Yantai Dongcheng Acquires Full Rights to Alfatide II, Targeting Diagnostic and Therapeutic Applications
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its acquisition of all rights to alfatide II across all diagnostic and therapeutic fields and indications. Alfatide II, initially developed by Dr. Chen Xiaoyuan and previously licensed to Jiangsu Xinrui Pharmaceutical Co., Ltd. for further development, is currently in the…
-
Yantai Dongcheng’s Radiopharmaceutical 68GaLNC1007 Gets FDA Nod for Diagnostic Use in Solid Tumors
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) for its radiopharmaceutical 68GaLNC1007. This diagnostic agent targets fibroblast activating protein (FAP) and integrin αvβ3 and is under development to support the treatment…
-
Yantai Dongcheng Pharmaceutical Gets NMPA Green Light for FAP-Targeting Radiotherapeutic Drug
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received approval from the National Medical Products Administration (NMPA) in China to proceed with a clinical study for its radiotherapeutic drug, 177Lu-LNC1004, which targets advanced solid tumors. The drug is designed to treat fibroblast activation protein (FAP)-positive…
-
Yantai Dongcheng Pharmaceutical Gets Green Light for Prostate Cancer Diagnostic Drug Trial
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that it has received ethical approval from Beijing Hospital to conduct a Phase III clinical study. The study will assess the diagnostic efficacy of a radionuclide candidate, intended for use with positron emission tomography (PET) imaging,…
-
Yantai Dongcheng Pharmaceutical and Eckert & Ziegler Form Joint Venture for Medical Isotopes
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a China-based pharmaceutical company, is poised to establish a joint venture (JV) with Germany’s Eckert & Ziegler Radiopharma Projekte UG. This strategic partnership aims to combine the expertise of both companies in the field of medical isotopes. Investment and JV FormationThe joint…
